The OncFive: Top Oncology Articles for the Week of 9/1 - OncLive
OncLive’s weekly roundup highlights FDA approvals, including afamitresgene autoleucel for synovial sarcoma, vorasidenib for astrocytoma/oligodendroglioma, CB-012 for AML, and companion diagnostics for olaparib/abiraterone in BRCA+ mCRPC. Interviews discuss targeted therapies in mCRC and ASCO’s health equity recommendations.
Related Clinical Trials
Reference News
FDA approves ribociclib for HR+/HER2– breast cancer, AMG 193 shows activity in MTAP-deleted tumors, pembrolizumab plus chemo for mesothelioma, neoadjuvant pembrolizumab/chemo boosts OS in TNBC, and experts discuss 2024 IASLC World Conference on Lung Cancer findings.
OncLive’s weekly roundup highlights FDA approvals, including afamitresgene autoleucel for synovial sarcoma, vorasidenib for astrocytoma/oligodendroglioma, CB-012 for AML, and companion diagnostics for olaparib/abiraterone in BRCA+ mCRPC. Interviews discuss targeted therapies in mCRC and ASCO’s health equity recommendations.